Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Deep learning-based classification of mesothelioma improves prediction of patient outcome.

Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N, Girard N, Elemento O, Nicholson AG, Blay JY, Galateau-Sallé F, Wainrib G, Clozel T.

Nat Med. 2019 Oct 7. doi: 10.1038/s41591-019-0583-3. [Epub ahead of print]

PMID:
31591589
2.

EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.

Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG 3rd, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Cree I, Rusch VW, Girard N, Galateau-Salle F.

J Thorac Oncol. 2019 Sep 20. pii: S1556-0864(19)33232-0. doi: 10.1016/j.jtho.2019.08.2506. [Epub ahead of print]

PMID:
31546041
3.

Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.

Marchevsky AM, Khoor A, Walts AE, Nicholson AG, Zhang YZ, Roggli V, Carney J, Roden AC, Tazelaar HD, Larsen BT, LeStang N, Chirieac LR, Klebe S, Tsao MS, De Perrot M, Pierre A, Hwang DM, Hung YP, Mino-Kenudson M, Travis W, Sauter J, Beasley MB, Galateau-Sallé F.

Mod Pathol. 2019 Sep 4. doi: 10.1038/s41379-019-0352-3. [Epub ahead of print]

PMID:
31485011
4.

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.

Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojsic J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L.

Nat Commun. 2019 Aug 20;10(1):3407. doi: 10.1038/s41467-019-11276-9.

5.

Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.

Le Stang N, Burke L, Blaizot G, Gibbs AR, Lebailly P, Clin B, Girard N, Galateau-Sallé F; MESOPATH and EURACAN networks.

Arch Pathol Lab Med. 2019 Aug 7. doi: 10.5858/arpa.2018-0457-OA. [Epub ahead of print]

PMID:
31389715
6.

Malignant mesothelioma in situ: morphologic features and clinical outcome.

Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao MS, Chang N, De Perrot M, Dacic S.

Mod Pathol. 2019 Aug 2. doi: 10.1038/s41379-019-0347-0. [Epub ahead of print]

PMID:
31375770
7.

In Reply to "Malignant Mesothelioma and Its Nonasbestos Causes".

Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL.

Arch Pathol Lab Med. 2019 Aug;143(8):911-914. doi: 10.5858/arpa.2019-0060-LE. No abstract available.

PMID:
31339754
8.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI.

CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8. Review.

9.

Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.

Dacic S, Le Stang N, Husain A, Weynand B, Beasley MB, Butnor K, Chapel D, Gibbs A, Klebe S, Lantuejoul S, Roden AC, Roggli V, Tazelaar H, Vignaud JM, Galateau-Sallé F.

Mod Pathol. 2019 Jul 4. doi: 10.1038/s41379-019-0320-y. [Epub ahead of print]

PMID:
31273316
10.

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.

Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS.

J Thorac Oncol. 2019 Oct;14(10):1704-1717. doi: 10.1016/j.jtho.2019.06.020. Epub 2019 Jun 28.

PMID:
31260832
11.

MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.

Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C, Galateau-Salle F, Hiroshima K, Krausz T, Le Stang N, McGregor S, Nabeshima K, Husain AN.

Mod Pathol. 2019 Jun 23. doi: 10.1038/s41379-019-0310-0. [Epub ahead of print]

PMID:
31231127
12.

Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study.

Le Stang N, Bouvier V, Glehen O, Villeneuve L; FRANCIM network; MESOPATH Referent National Center, Galateau-Sallé F, Clin B.

Cancer Epidemiol. 2019 Jun;60:106-111. doi: 10.1016/j.canep.2019.03.014. Epub 2019 Apr 3.

PMID:
30953970
13.

Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.

Duplaquet L, Figeac M, Leprêtre F, Frandemiche C, Villenet C, Sebda S, Sarafan-Vasseur N, Bénozène M, Vinchent A, Goormachtigh G, Wicquart L, Rousseau N, Beaussire L, Truant S, Michel P, Sabourin JC, Galateau-Sallé F, Copin MC, Zalcman G, De Launoit Y, Fafeur V, Tulasne D.

Mol Cancer Ther. 2019 Jun;18(6):1137-1148. doi: 10.1158/1535-7163.MCT-18-0582. Epub 2019 Mar 29.

PMID:
30926633
14.

ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.

PMID:
30361252
15.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
16.

Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.

Churg A, Nabeshima K, Ali G, Bruno R, Fernandez-Cuesta L, Galateau-Salle F.

Lung Cancer. 2018 Oct;124:95-101. doi: 10.1016/j.lungcan.2018.07.041. Epub 2018 Jul 30.

PMID:
30268487
17.

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Franconieri F, Deshayes S, de Boysson H, Trad S, Martin Silva N, Terrier B, Bienvenu B, Galateau-Sallé F, Emile JF, Johnson AC, Aouba A.

Oncoimmunology. 2018 Apr 9;7(8):e1450712. doi: 10.1080/2162402X.2018.1450712. eCollection 2018.

18.

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N.

J Thorac Oncol. 2018 Aug;13(8):1189-1203. doi: 10.1016/j.jtho.2018.04.023. Epub 2018 Apr 30.

19.

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

Lantuejoul S, Adam J, Girard N, Duruisseaux M, Mansuet-Lupo A, Cazes A, Rouquette I, Gibault L, Garcia S, Antoine M, Vignaud JM, Galateau-Sallé F, Sagan C, Badoual C, Penault-Llorca F, Damotte D; pour le groupe pathologistes thoraciques de valorisation de l’expertise, de la recherche et de l’innovation (PATTERN). Fondation Synergie Lyon Cancer.

Ann Pathol. 2018 Apr;38(2):110-125. doi: 10.1016/j.annpat.2018.01.007. Epub 2018 Mar 21. French.

PMID:
29571563
20.

Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.

Nicholson AG, Tsao MS, Travis WD, Patil DT, Galateau-Salle F, Marino M, Dacic S, Beasley MB, Butnor KJ, Yatabe Y, Pass HI, Rusch VW, Detterbeck FC, Asamura H, Rice TW, Rami-Porta R.

Arch Pathol Lab Med. 2018 May;142(5):645-661. doi: 10.5858/arpa.2017-0245-RA. Epub 2018 Feb 26. Review.

PMID:
29480761
21.

Malignant Mesothelioma and Its Non-Asbestos Causes.

Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL.

Arch Pathol Lab Med. 2018 Jun;142(6):753-760. doi: 10.5858/arpa.2017-0365-RA. Epub 2018 Feb 26. Review.

PMID:
29480760
22.

Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.

Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, Husain AN.

Mod Pathol. 2018 Apr;31(4):598-606. doi: 10.1038/modpathol.2017.170. Epub 2018 Jan 12.

23.

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Marchevsky AM, LeStang N, Hiroshima K, Pelosi G, Attanoos R, Churg A, Chirieac L, Dacic S, Husain A, Khoor A, Klebe S, Lantuejoul S, Roggli V, Vignaud JM, Weynard B, Sauter J, Henderson D, Nabeshima K, Galateau-Salle F.

Hum Pathol. 2017 Sep;67:160-168. doi: 10.1016/j.humpath.2017.07.015. Epub 2017 Aug 4. Review.

PMID:
28782639
24.

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR.

Arch Pathol Lab Med. 2018 Jan;142(1):89-108. doi: 10.5858/arpa.2017-0124-RA. Epub 2017 Jul 7.

PMID:
28686500
25.

Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis.

Le Pendu C, Meignin V, Gonzalez-Chiappe S, Hij A, Galateau-Sallé F, Mahr A.

J Rheumatol. 2017 Jul;44(7):1039-1043. doi: 10.3899/jrheum.170061. Epub 2017 May 1.

PMID:
28461644
26.

PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

Lantuejoul S, Le Stang N, Damiola F, Scherpereel A, Galateau-Sallé F.

J Thorac Oncol. 2017 May;12(5):778-781. doi: 10.1016/j.jtho.2017.03.018. No abstract available.

27.

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.

Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M.

J Thorac Oncol. 2017 Apr;12(4):724-733. doi: 10.1016/j.jtho.2016.12.019. Epub 2016 Dec 27.

28.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.

Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025.

29.

The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.

Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions.

J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. Epub 2016 Sep 28.

30.

Pathology of Asbestosis: An Update of the Diagnostic Criteria Response to a Critique.

Roggli V, Gibbs AR, Attanoos R, Churg A, Popper H, Corrin B, Franks T, Galateau-Salle F, Galvin J, Hasleton P, Honma K.

Arch Pathol Lab Med. 2016 Sep;140(9):950-2. doi: 10.5858/arpa.2015-0503-SA. No abstract available.

PMID:
27575267
31.

Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.

Chirac P, Maillet D, Leprêtre F, Isaac S, Glehen O, Figeac M, Villeneuve L, Péron J, Gibson F, Galateau-Sallé F, Gilly FN, Brevet M.

Hum Pathol. 2016 Sep;55:72-82. doi: 10.1016/j.humpath.2016.04.015. Epub 2016 May 14.

PMID:
27184482
32.

Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Churg A, Attanoos R, Borczuk AC, Chirieac LR, Galateau-Sallé F, Gibbs A, Henderson D, Roggli V, Rusch V, Judge MJ, Srigley JR.

Arch Pathol Lab Med. 2016 Oct;140(10):1104-10. doi: 10.5858/arpa.2016-0073-OA. Epub 2016 Mar 31.

33.

Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.

Franconieri F, Martin-Silva N, de Boysson H, Galateau-Salle F, Emile JF, Bienvenu B, Aouba A.

Acta Oncol. 2016 Jul;55(7):930-2. doi: 10.3109/0284186X.2015.1120885. Epub 2016 Mar 31. No abstract available.

PMID:
27031008
34.

Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.

Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.

Hum Pathol. 2016 Jun;52:9-18. doi: 10.1016/j.humpath.2016.01.010. Epub 2016 Feb 5.

PMID:
26980049
35.

[The man who just wanted to quit smoking…].

Audemard-Verger A, Lepennec V, Galateau-Salle F, Verdon R.

Rev Mal Respir. 2016 Mar;33(3):264-6. doi: 10.1016/j.rmr.2015.06.018. Epub 2016 Feb 5. French. No abstract available.

PMID:
26857199
36.

Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).

Bienvenu B, Ly KH, Lambert M, Agard C, André M, Benhamou Y, Bonnotte B, de Boysson H, Espitia O, Fau G, Fauchais AL, Galateau-Sallé F, Haroche J, Héron E, Lapébie FX, Liozon E, Luong Nguyen LB, Magnant J, Manrique A, Matt M, de Menthon M, Mouthon L, Puéchal X, Pugnet G, Quemeneur T, Régent A, Saadoun D, Samson M, Sène D, Smets P, Yelnik C, Sailler L, Mahr A; Groupe d’Étude Français des Artérites des gros Vaisseaux, under the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires Rares.

Rev Med Interne. 2016 Mar;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015. Epub 2016 Jan 29.

PMID:
26833145
37.

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.

Galateau-Salle F, Churg A, Roggli V, Travis WD; World Health Organization Committee for Tumors of the Pleura.

J Thorac Oncol. 2016 Feb;11(2):142-54. doi: 10.1016/j.jtho.2015.11.005. Review.

38.

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.

Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Sallé F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F.

Nat Genet. 2015 Oct;47(10):1200-5. doi: 10.1038/ng.3399. Epub 2015 Sep 7.

PMID:
26343384
39.

Digestive cancers and occupational asbestos exposure: incidence study in a cohort of asbestos plant workers.

Boulanger M, Morlais F, Bouvier V, Galateau-Salle F, Guittet L, Marquignon MF, Paris C, Raffaelli C, Launoy G, Clin B.

Occup Environ Med. 2015 Nov;72(11):792-7. doi: 10.1136/oemed-2015-102871. Epub 2015 Aug 24.

PMID:
26304776
40.

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

Churg A, Sheffield BS, Galateau-Salle F.

Arch Pathol Lab Med. 2016 Apr;140(4):318-21. doi: 10.5858/arpa.2015-0240-SA. Epub 2015 Aug 19.

PMID:
26288396
41.

French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.

Lantuejoul S, Rouquette I, Blons H, Le Stang N, Ilie M, Begueret H, Grégoire V, Hofman P, Gros A, Garcia S, Monhoven N, Devouassoux-Shisheboran M, Mansuet-Lupo A, Thivolet F, Antoine M, Vignaud JM, Penault-Llorca F, Galateau-Sallé F, McLeer-Florin A.

Eur Respir J. 2015 Jul;46(1):207-18. doi: 10.1183/09031936.00119914. Epub 2015 Apr 30.

42.

[Hepatic abnormality].

Deshayes S, Galateau-Sallé F, de La Blanchardière A.

Rev Med Interne. 2015 May;36(5):363-4. doi: 10.1016/j.revmed.2014.06.002. Epub 2014 Jul 22. French. No abstract available.

PMID:
25063545
43.

Cardiac involvement in relapsing polychondritis.

Gautier M, Boutemy J, Ivascau C, Galateau-Salle F, Labombarda F.

Eur Heart J. 2014 Sep 1;35(33):2241. doi: 10.1093/eurheartj/ehu238. Epub 2014 Jun 10. No abstract available.

PMID:
24917640
44.

Role of metal oxide nanoparticles in histopathological changes observed in the lung of welders.

Andujar P, Simon-Deckers A, Galateau-Sallé F, Fayard B, Beaune G, Clin B, Billon-Galland MA, Durupthy O, Pairon JC, Doucet J, Boczkowski J, Lanone S.

Part Fibre Toxicol. 2014 May 13;11:23. doi: 10.1186/1743-8977-11-23.

45.

Two cases of aggressive nontumoral folliculotropic mycosis fungoides with visceral involvement.

Brugière C, Karanian-Philippe M, Comoz F, Dompmartin A, Galateau-Sallé F, Verneuil L.

Br J Dermatol. 2014 Oct;171(4):899-902. doi: 10.1111/bjd.13083. Epub 2014 Sep 7.

PMID:
24779866
46.

[The French mesothelioma network from 1998 to 2013].

Galateau-Sallé F, Gilg Soit Ilg A, Le Stang N, Brochard P, Pairon JC, Astoul P, Frenay C, Blaizot G, Chamming's S, Ducamp S, Rousvoal T, de Quillacq A, Abonnet V, Abdalsamad I, Begueret H, Brambilla E, Capron F, Copin MC, Danel C, de Lajartre AY, Foulet-Roge A, Garbe L, Groussard O, Giusiano S, Hofman V, Lantuejoul S, Piquenot JM, Rouquette I, Sagan C, Thivolet-Bejui F, Vignaud JM, Scherpereel A, Jaurand MC, Jean D, Hainaut P, Chérié-Challine L, Goldberg M, Luce D, Imbernon E.

Ann Pathol. 2014 Feb;34(1):51-63. doi: 10.1016/j.annpat.2014.01.009. Epub 2014 Feb 26. French.

47.

Well-differentiated papillary mesothelioma with invasive foci.

Churg A, Allen T, Borczuk AC, Cagle PT, Galateau-Sallé F, Hwang H, Murer B, Murty VV, Ordonez N, Tazelaar HD, Wick M.

Am J Surg Pathol. 2014 Jul;38(7):990-8. doi: 10.1097/PAS.0000000000000200.

PMID:
24618613
48.

Giant-cell aortitis: an unusual case of Bentall operation.

Lemaire A, Cuttone F, Caprio S, Massetti M, Galateau-Salle F.

Asian Cardiovasc Thorac Ann. 2014 Mar;22(3):342-4. doi: 10.1177/0218492312470669. Epub 2013 Jul 16.

PMID:
24585914
49.

A misleading cause of pseudo-thymic tumor in ectopic Cushing's syndrome.

Icard P, Heyndrickx M, Galateau-Salle F, Resnik Y.

Asian Cardiovasc Thorac Ann. 2013 Apr;21(2):224-6. doi: 10.1177/0218492312450290.

PMID:
24532629
50.

Socioeconomic environment and cancer incidence: a French population-based study in Normandy.

Bryere J, Dejardin O, Bouvier V, Colonna M, Guizard AV, Troussard X, Pornet C, Galateau-Salle F, Bara S, Launay L, Guittet L, Launoy G.

BMC Cancer. 2014 Feb 13;14:87. doi: 10.1186/1471-2407-14-87.

Supplemental Content

Loading ...
Support Center